| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
61,556,000 |
| Market
Cap: |
2.83(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$29.94 - $45.43 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Co.'s products include Trokendi XR and Oxtellar XR, which are the once-daily extended release topiramate and oxcarbazepine products indicated for the treatment of epilepsy; APOKYN, which is a product indicated for the intermittent treatment of hypomobility or off episodes in patients with Parkinson's Disease (PD); XADAGO, which is an once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD; and MYOBLOC, which is a product indicated for the treatment of cervical dystonia and sialorrhea in adults.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
277,484 |
277,484 |
635,964 |
755,172 |
| Total Sell Value |
$12,081,676 |
$12,081,676 |
$25,139,566 |
$29,069,092 |
| Total People Sold |
6 |
6 |
9 |
10 |
| Total Sell Transactions |
13 |
13 |
26 |
36 |
| End Date |
2025-06-12 |
2025-03-11 |
2024-09-10 |
2023-09-11 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Khattar Jack A. |
President, CEO |
• • – |
2025-09-08 |
4 |
AS |
$46.29 |
$292,645 |
D/D |
(6,322) |
1,111,983 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-09-08 |
4 |
OE |
$25.30 |
$204,272 |
D/D |
8,074 |
1,118,305 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-09-05 |
4 |
AS |
$46.01 |
$2,557,144 |
D/D |
(55,578) |
1,110,231 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-09-05 |
4 |
OE |
$25.30 |
$1,851,353 |
D/D |
73,176 |
1,165,809 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-08-28 |
4 |
AS |
$45.12 |
$1,089,648 |
D/D |
(24,150) |
1,092,633 |
|
1% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-08-28 |
4 |
OE |
$12.98 |
$503,351 |
D/D |
38,779 |
1,116,783 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-08-27 |
4 |
AS |
$45.05 |
$479,783 |
D/D |
(10,650) |
1,078,004 |
|
2% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-08-27 |
4 |
OE |
$12.98 |
$223,191 |
D/D |
17,195 |
1,088,654 |
|
- |
|
| Newhall Charles W III |
Director |
– • – |
2025-08-27 |
4 |
AS |
$45.01 |
$161,496 |
D/D |
(3,588) |
129,644 |
|
2% |
|
| Newhall Charles W III |
Director |
– • – |
2025-08-25 |
4 |
AS |
$45.00 |
$45,000 |
D/D |
(1,000) |
133,232 |
|
4% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-08-25 |
4 |
AS |
$45.00 |
$45,000 |
D/D |
(1,000) |
1,071,459 |
|
4% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-08-25 |
4 |
OE |
$12.98 |
$20,911 |
D/D |
1,611 |
1,072,459 |
|
- |
|
| Mottola Frank |
SVP, Quality, GMP, Ops, IT |
• – – |
2025-08-25 |
4 |
S |
$44.51 |
$623,140 |
D/D |
(14,000) |
15,496 |
|
-4% |
|
| Mottola Frank |
SVP, Quality, GMP, Ops, IT |
• – – |
2025-08-25 |
4 |
OE |
$12.98 |
$181,720 |
D/D |
14,000 |
29,496 |
|
- |
|
| Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
• – – |
2025-08-25 |
4 |
D |
$41.46 |
$24,088 |
D/D |
(581) |
13,718 |
|
- |
|
| Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
• – – |
2025-08-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,250 |
14,299 |
|
- |
|
| Newhall Charles W III |
Director |
– • – |
2025-08-22 |
4 |
AS |
$45.00 |
$63,540 |
D/D |
(1,412) |
134,232 |
|
3% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-08-22 |
4 |
AS |
$45.00 |
$67,500 |
D/D |
(1,500) |
1,070,848 |
|
3% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-08-22 |
4 |
OE |
$12.98 |
$31,347 |
D/D |
2,415 |
1,072,348 |
|
- |
|
| Dec Timothy C |
Senior Vice-President & CFO |
• – – |
2025-08-22 |
4 |
S |
$44.49 |
$524,092 |
D/D |
(11,780) |
1,246 |
|
-3% |
|
| Hudson Frederick M. |
Director |
– • – |
2025-08-14 |
4 |
S |
$42.26 |
$315,133 |
D/D |
(7,457) |
46,307 |
|
-9% |
|
| Sensenig Bethany |
Director |
– • – |
2025-08-14 |
4 |
AS |
$42.25 |
$226,840 |
D/D |
(5,369) |
0 |
|
9% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-08-06 |
4 |
AS |
$40.24 |
$5,883,360 |
D/D |
(140,000) |
1,069,933 |
|
8% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-08-06 |
4 |
OE |
$12.98 |
$3,613,225 |
D/D |
201,250 |
1,133,433 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-04-02 |
4 |
D |
$0.00 |
$0 |
I/I |
(16,850) |
1,005,600 |
|
- |
|
394 Records found
|
|
Page 1 of 16 |
|
|
0.21 (0.46%) 
